PTC THERAPEUTICS, INC.(PTCT)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
PTC THERAPEUTICS, INC. (PTCT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PTCT at 35.4/100 on a 32-signal composite quality model, placing it at rank #2,306 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (21.3) and profitability (22.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 26.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), PTC THERAPEUTICS, INC. reports quarterly revenue of $360.5M, net income of $83.5M, free cash flow of $126.9M. Top institutional holders of PTCT by reported 13-F value include BlackRock, RTW INVESTMENTS, Jupiter Topco, based on the most recent SEC filings. PTCT trades on the Nasdaq exchange and files with the SEC under CIK 1070081. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PTCT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PTC THERAPEUTICS, INC. directly from SEC EDGAR.
AI Quality Score
35.4/100
AI Rank
#2,306
Revenue
$360.5M
Net Income
$83.5M
Free Cash Flow
$126.9M
PTCT key financials by period
PTC THERAPEUTICS, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$1.7B
$682.6M
50.1%
FY 2024
10-K
$806.8M
$-363.3M
-37.5%
FY 2023
10-K
$937.8M
$-626.6M
-46.9%
FY 2022
10-K
$698.8M
$-559.0M
-64.0%
FY 2021
10-K
$538.6M
$-523.9M
-69.5%
FY 2020
10-K
$380.8M
$-438.2M
-113.4%
Institutions holding PTCT
Institutional investors reporting a position in PTC THERAPEUTICS, INC. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-05-07 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Net product revenue surged 47% YoY to $225.6M driven by Sephience launch, but collaboration revenue plummeted from $989.8M in Q1 2025 (Novartis upfront) to near-zero.
Biggest Revenue Drivers
Net product revenue$225.6M+47% YoY
Increase primarily from Sephience ($124.6M), newly launched, partially offset by declines in Emflaza ($21.5M) due to generic competition and Translarna ($59.0M) due to EC's adoption of negative opinion.
Royalty revenue$46.8M+29% YoY
Higher Evrysdi sales drove royalties; company received $46.8M vs. $36.4M YoY from Roche SMA program.
Biggest Revenue Drivers
Total revenue: $272.6M-77% YoY
Net product revenue$225.6M+47% YoY
Increase primarily from Sephience ($124.6M), newly launched, partially offset by declines in Emflaza ($21.5M) due to generic competition and Translarna ($59.0M) due to EC's adoption of negative opinion.
Royalty revenue$46.8M+29% YoY
Higher Evrysdi sales drove royalties; company received $46.8M vs. $36.4M YoY from Roche SMA program.
Collaboration and license revenue$0.1M-100% YoY
Q1 2025 included $989.8M Novartis upfront payment (transaction closed January 2025); Q1 2026 reflects only $0.1M for ongoing work.
Largest Expense Items
Cost of product, collaboration and license sales (excl. amortization)$28.0M+$15.2M YoY
Increase from Novartis agreement costs, Upstaza/Kebilidi royalties, and new product launches.
Research and development$100.9M-7% YoY
Decrease reflects focus on differentiated programs; reductions in Global DMD, Gene Therapy, Splicing platform, and Sephience development.
Interest expense, net$49.0M+44% YoY
Increase driven by higher non-cash interest on liability for sale of future royalties (Royalty Pharma A&R agreement).
Selling, general and administrative$86.2M+6% YoY
Increase reflects continued commercial investment supporting expanding product portfolio.
Margins: Gross margin on product sales declined significantly due to higher cost of goods and amortization of intangible assets (Sephience and Upstaza/Kebilidi regulatory milestone costs being amortized). Operating income turned to a loss of $45M vs. profit of $970M YoY, primarily due to the massive decline in collaboration revenue (no repeat of Novartis $1B upfront).
Watch Items from the Filing
Translarna revenue at risk: EC adopted negative opinion in March 2025; company withdrew U.S. NDA in February 2026. Revenue fell 31% YoY to $59.0M; further declines expected as individual EU countries assess continued access. Substantial revenue loss risk.
Emflaza orphan exclusivity cliff: Seven-year U.S. orphan exclusivity for ages 5+ expired February 2024, driving generic competition. Remaining exclusivity for ages 2–4 expires June 2026. Revenue declined 55% YoY to $21.5M.
Novartis votoplam milestone triggered in April 2026: $50M development milestone achieved upon Phase 3 trial initiation (subsequent event). Company eligible for up to $1.9B in total milestones plus profit share and royalties.
Three distributors each represent >10% of net product sales in Q1 2026; customer concentration creates pricing and supply chain risk.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
